|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pencik J, Pham HT, Schmoellerl J, Javaheri
T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F and Kenner
L: JAK-STAT signaling in cancer: From cytokines to non-coding
genome. Cytokine. 87:26–36. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu Y, Zhao Q, Wang Z and Liu XY: Activated
STAT3 correlates with prognosis of non-small cell lung cancer and
indicates new anticancer strategies. Cancer Chemother Pharmacol.
75:917–922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song Q, Liu B, Li X, Zhang Q, Cao L, Xu M,
Meng Z, Wu X and Xu K: MiR-26a-5p potentiates metastasis of human
lung cancer cells by regulating ITGβ8- JAK2/STAT3 axis. Biochem
Biophys Res Commun. 501:494–500. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilson VG: Introduction to sumoylation.
Adv Exp Med Biol. 963:1–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang Y, He Y, Wang X, Liang Z, He G, Zhang
P, Zhu H, Xu N and Liang S: Protein SUMOylation modification and
its associations with disease. Open Biol. 7:1701672017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Chen Z, Zhou Z, Yang P and Wang
CY: Sumoylation modulates the susceptibility to type 1 diabetes.
Adv Exp Med Biol. 963:299–322. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li H, Yang Z, Pu LM, Li X, Ruan Y, Yang F,
Meng S, Yang D, Yao W, Fu H, et al: Adiponectin receptor 1 and
small ubiquitin-like modifier 4 polymorphisms are associated with
risk of coronary artery disease without diabetes. J Geriatr
Cardiol. 13:776–782. 2016.PubMed/NCBI
|
|
10
|
Alzolibani AA, Settin A, Ahmed AA, Ismail
H, Elhefni N and Robaee AA: Genetic polymorphisms of NFκB1 −94
del/ins ATTG, NFκB1A 2758 A>G and SUMO rs237025 G>A in
psoriasis. Int J Health Sci (Qassim). 9:25–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hou S, Kijlstra A and Yang P: The genetics
of behçet's disease in a Chinese population. Front Med. 6:354–359.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen S, Yang T, Liu F, Guo Y, Yang H, Xu
J, Song J, Zhu Z and Liu D: Inflammatory factor-specific
sumoylation regulates NF-κB signalling in glomerular cells from
diabetic rats. Inflamm Res. 63:23–31. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mo YY, Yu Y, Ee PL and Beck WT:
Overexpression of a dominant negative mutant Ubc9 is associated
with increased sensitivity to anticancer drugs. Cancer Res.
64:2793–2798. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang CY and She JX: SUMO4 and its role in
type I diabetes pathogenesis. Diabetes Metab Res Rev. 24:93–102.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shen QY, Wu HH, Liang JX, XU JY and Liang
Y: Clinical significance of SUMO4 expression in papillary thyroid
carcinoma. Chin J Pathophysiology. 31:1422–1426. 2015.
|
|
16
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours, International Union
Against Cancer. 7th. A John Wiley & Sons, Ltd., Publication;
2009, http://www.inen.sld.pe/portal/documentos/pdf/educacion/13072015_TNM%20Classification.pdf
|
|
17
|
Gillett CE: Immunohistochemistry. Methods
Mol Med. 120:191–200. 2006.PubMed/NCBI
|
|
18
|
Wilson VG and Rangasamy D: Incellular
targeting of proteins by sumoylation. Exp Cell Res. 271:57–65.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sarge KD and Park-Sarge OK: Sumo and its
role in human diseases. Int Rev Cell Mol Biol. 288:167–183. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang HJ, Zhou LL, Fu WJ, Zhang CY, Jiang
H, Du J and Hou J: β-Catenin SUMOylation is involved in the
dysregulated proliferation of myeloma cells. Am J Cancer Res.
5:309–320. 2014.PubMed/NCBI
|
|
21
|
Bellail AC, Olson JJ and Hao C: SUMO1
modification stabilizes CDK6 protein and drives the cell cycle and
glioblastoma progression. Nat Commun. 23:42342014. View Article : Google Scholar
|
|
22
|
Nestal de Moraes G, Ji Z, Fan LY, Yao S,
Zona S, Sharrocks AD and Lam EW: SUMOylation modulates
FOXK2-mediated paclitaxel sensitivity in breast cancer cells.
Oncogenesis. 7:292018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo D, Li M, Zhang Y, Yang P, Eckenrode S,
Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, et al: A
functional variant of sumo4, a new i kappa b alpha modifier, is
associated with type 1 diabetes. Nat Genet. 36:837–841. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bohren KM, Nadkarni V, Song JH, Gabbay KH
and Owerbach D: A M55V polymorphism in a novel SUMO gene (SUMO-4)
differentially activates heat shock transcription factors and is
associated with susceptibility to type I diabetes mellitus. J Biol
Chem. 279:27233–27238. 2004. View Article : Google Scholar : PubMed/NCBI
|
